StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN)

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and set a $5.00 target price on shares of Trevena in a report on Thursday, November 14th.

Trevena Trading Up 0.6 %

TRVN stock opened at $1.67 on Friday. The stock has a 50-day moving average price of $1.73 and a two-hundred day moving average price of $2.57. The stock has a market cap of $1.44 million, a PE ratio of -0.04 and a beta of 1.08. Trevena has a 1 year low of $1.13 and a 1 year high of $17.50.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.